Full text is available at the source.
New Horizons in Metabolic Health: Unveiling the Future of Drug Discovery and Development
New Advances in Metabolic Health and Future Drug Development
AI simplified
Abstract
Key drug targets for metabolic diseases include PPARs, AMPK, and gut microbiota-derived SCFAs.
- PPARs are associated with improving insulin resistance.
- AMPK plays a role in regulating energy metabolism.
- Innovative drugs like GLP-1 receptor agonists and SGLT2 inhibitors show efficacy in glycemic control and liver protection.
- AI and CRISPR technologies may accelerate drug development.
- Interindividual variability in microbiota presents challenges for treatment.
- Long-term safety of new drugs is still under investigation.
AI simplified